top of page
Cancer Vaccine Institute News


Vaccines to Prevent Ovarian Cancer Recurrence
The biggest challenge in ovarian cancer isn’t getting to remission - it’s staying there. Recurrence rates are high, especially for advanced disease. Nineteen-year survivor and CVI vaccine recipient Jamie Crase captures that stark reality: “Stage 4 ovarian cancer has a 90-95% chance of recurrence after the initial treatment. The odds were not in my favor.” At the Cancer Vaccine Institute, we are changing the odds in the favor of Jamie and all patients diagnosed with this deadl

Sarah White
Sep 15


Ovarian Cancer Awareness Month: From Awareness to Action
For those impacted by ovarian cancer, September is more than just another month. It’s Ovarian Cancer Awareness Month, a time to raise awareness for a disease that remains underfunded and underrecognized, and a moment for patients and families to be truly seen and heard as we push for the breakthroughs they’ve waited far too long for. Ovarian cancer is especially challenging because there are no reliable tests to catch it early. Most people are diagnosed after the disease is a

Sarah White
Sep 4


Midyear Review from the Cancer Vaccine Institute
The first half of 2026 has been an exciting one at the Cancer Vaccine Institute (CVI), and we are proud to share the progress we’ve made in our Midyear Review. We have six clinical trials actively recruiting, with four additional studies opening soon. Our faculty and research teams have been recognized through competitive awards, invited presentations, and impactful scientific publications. These achievements highlight the significance of our work and elevate the visibility o

Sarah White
Aug 20


Dr. Nora Disis Selected as Fellow of the Academy of Immuno-Oncology by SITC
Photo Credits: Lisa Stromme Warren The Cancer Vaccine Institute is proud to celebrate Dr. Nora Disis, CVI Director, on her selection as a 2026 Fellow of the Academy of Immuno-Oncology by the Society for Immunotherapy of Cancer (SITC). This distinction honors scientific leaders whose work has made significant contributions to the field of cancer immunotherapy. Dr. Disis joins a distinguished class of scientific leaders who have made contributions that have shaped cancer immuno

Sarah White
Aug 17


What makes a cancer vaccine work for years? Insights from Dr. John Liao and Dr. Nora Disis
Research from the Cancer Vaccine Institute and others points to a near-term future in which cancer vaccines will play an instrumental role in managing cancer. Therapeutic cancer vaccines are designed to help the immune system recognize and attack cancer cells. A key part of this response is generating T-cells, immune cells, that specifically recognize cancer proteins and create a cancer-killing immune response. Some T-cells become “memory” T-cells, remaining in the body long

Sarah White
Jun 23
Blog: Blog2
bottom of page
